The Life Sciences team advised Cognition Therapeutics on the closing of a securities purchase agreement for the purchase and sale of 14,700,000 shares of its common stock pursuant to a registered direct offering. The offering resulted in gross proceeds of approximately $30 million, before deducting placement agent fees and other offering expenses. The offering closed on August 29, 2025. Cognition Therapeutics intends to use the net proceeds to fund preparation for the Phase 3 programs of zervimesine in neurodegenerative disorders, as well as for working capital and general corporate purposes.
Cognition Therapeutics is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. The company recently completed Phase 2 studies of the lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START study (NCT05531656) in early Alzheimer’s disease is ongoing with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
The Goodwin deal team consisted of Rachael Bushey, Justin Platt, Claire Treesh, Jason Wu, Julia Shaver, and Maggie Wong.
For more information about the deal, please read the press release.